Compare HNVR & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HNVR | DRUG |
|---|---|---|
| Founded | 2008 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Pharmaceuticals and Biotechnology |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 191.4M | 228.0M |
| IPO Year | 2022 | 2020 |
| Metric | HNVR | DRUG |
|---|---|---|
| Price | $21.97 | $20.38 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | $26.50 | ★ $107.47 |
| AVG Volume (30 Days) | 17.5K | ★ 263.1K |
| Earning Date | 10-28-2026 | 08-17-2026 |
| Dividend Yield | ★ 1.82% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.40 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $15.72 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $20.19 | $17.40 |
| 52 Week High | $27.94 | $123.75 |
| Indicator | HNVR | DRUG |
|---|---|---|
| Relative Strength Index (RSI) | 32.32 | 26.33 |
| Support Level | $20.71 | $17.40 |
| Resistance Level | $22.39 | $58.93 |
| Average True Range (ATR) | 0.96 | 3.39 |
| MACD | 0.01 | -0.58 |
| Stochastic Oscillator | 20.37 | 7.04 |
Hanover Bancorp Inc is a community commercial bank focused on providing personalized and efficient services and products tailored to local needs. The Bank offers a full range of financial services, including a complete suite of consumer, commercial, and municipal banking products such as multifamily and commercial mortgages, government-guaranteed loans, residential loans, business loans, and lines of credit. In addition, it provides customers with access to 24-hour ATM services with no fees, interest-bearing free checking accounts, telephone banking, mobile and internet banking solutions for both consumer and business clients, and safe deposit boxes.
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.